<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1405-9940</journal-id>
<journal-title><![CDATA[Archivos de cardiología de México]]></journal-title>
<abbrev-journal-title><![CDATA[Arch. Cardiol. Méx.]]></abbrev-journal-title>
<issn>1405-9940</issn>
<publisher>
<publisher-name><![CDATA[Instituto Nacional de Cardiología Ignacio Chávez]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1405-99402024000700001</article-id>
<article-id pub-id-type="doi">10.24875/acm.m24000097</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Posicionamiento mexicano para el diagnóstico y tratamiento de amiloidosis cardiaca]]></article-title>
<article-title xml:lang="en"><![CDATA[Mexican position paper for the diagnosis and treatment of cardiac amyloidosis]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Berrios-Bárcenas]]></surname>
<given-names><![CDATA[Enrique A.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Cigarroa-López]]></surname>
<given-names><![CDATA[José A.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
<xref ref-type="aff" rid="A a"/>
<xref ref-type="aff" rid="A5"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Cossio-Aranda]]></surname>
<given-names><![CDATA[Jorge E.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Vásquez-Ortiz]]></surname>
<given-names><![CDATA[Zuilma Y.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
<xref ref-type="aff" rid="A a"/>
<xref ref-type="aff" rid="A9"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Rodríguez-Díez]]></surname>
<given-names><![CDATA[Gerardo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="A a"/>
<xref ref-type="aff" rid="A11"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Baeza-Herrera]]></surname>
<given-names><![CDATA[Luis]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Cordero-Cabra]]></surname>
<given-names><![CDATA[Juan]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Morales-Portano]]></surname>
<given-names><![CDATA[Julieta]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Alexanderson-Rosas]]></surname>
<given-names><![CDATA[Erick]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Carvajal-Juárez]]></surname>
<given-names><![CDATA[Isabel]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Álvarez-Sangabriel]]></surname>
<given-names><![CDATA[Amada]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Jordán-Ríos]]></surname>
<given-names><![CDATA[Antonio]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ivey-Miranda]]></surname>
<given-names><![CDATA[Juan B.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Escalante-Seyffert]]></surname>
<given-names><![CDATA[Cecilia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Grimaldo]]></surname>
<given-names><![CDATA[Flavio A.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Hernández-Reyes]]></surname>
<given-names><![CDATA[Pablo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Laínez-Zelaya]]></surname>
<given-names><![CDATA[José S.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Lara-Vargas]]></surname>
<given-names><![CDATA[Jorge A.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Meave-González]]></surname>
<given-names><![CDATA[Aloha]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ibarra-Ibarra]]></surname>
<given-names><![CDATA[Blanca R.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Koretzky]]></surname>
<given-names><![CDATA[Solange G.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
<xref ref-type="aff" rid="A5"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Magaña-Serrano]]></surname>
<given-names><![CDATA[Antonio]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
<xref ref-type="aff" rid="A a"/>
<xref ref-type="aff" rid="A5"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Instituto Nacional de Cardiología Ignacio Chávez  ]]></institution>
<addr-line><![CDATA[ Ciudad de México]]></addr-line>
<country>México</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Hospital Español de México  ]]></institution>
<addr-line><![CDATA[ Ciudad de México]]></addr-line>
<country>México</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Instituto Mexicano del Seguro Social Hospital de Cardiología Centro Médico Nacional Siglo XXI ]]></institution>
<addr-line><![CDATA[ Ciudad de México]]></addr-line>
<country>México</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,Asociación Mexicana de Insuficiencia Cardiaca  ]]></institution>
<addr-line><![CDATA[ Ciudad de México]]></addr-line>
<country>México</country>
</aff>
<aff id="Af5">
<institution><![CDATA[,Asociación Nacional de Cardiólogos de México  ]]></institution>
<addr-line><![CDATA[ Ciudad de México]]></addr-line>
<country>México</country>
</aff>
<aff id="Af6">
<institution><![CDATA[,Sociedad Mexicana de Cardiología  ]]></institution>
<addr-line><![CDATA[ Ciudad de México]]></addr-line>
<country>México</country>
</aff>
<aff id="Af7">
<institution><![CDATA[,Instituto Nacional de Nutrición Salvador Zubirán  ]]></institution>
<addr-line><![CDATA[ Ciudad de México]]></addr-line>
<country>México</country>
</aff>
<aff id="Af8">
<institution><![CDATA[,Sociedad Nacional de Ecocardiografía de México  ]]></institution>
<addr-line><![CDATA[ Ciudad de México]]></addr-line>
<country>México</country>
</aff>
<aff id="Af9">
<institution><![CDATA[,Centro Médico ABC Santa Fe  ]]></institution>
<addr-line><![CDATA[ Ciudad de México]]></addr-line>
<country>México</country>
</aff>
<aff id="A10">
<institution><![CDATA[,Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado Centro Médico Nacional 20 de Noviembre ]]></institution>
<addr-line><![CDATA[ Ciudad de México]]></addr-line>
<country>México</country>
</aff>
<aff id="A11">
<institution><![CDATA[,Sociedad Mexicana de Electrofisiología y Estimulación Cardiaca  ]]></institution>
<addr-line><![CDATA[ Ciudad de México]]></addr-line>
<country>México</country>
</aff>
<aff id="A12">
<institution><![CDATA[,Hospital Regional de Alta Especialidad de la Península de Yucatán  ]]></institution>
<addr-line><![CDATA[ Ciudad de México]]></addr-line>
<country>México</country>
</aff>
<aff id="A13">
<institution><![CDATA[,Hospital Puerta de Hierro Norte  ]]></institution>
<addr-line><![CDATA[ Ciudad de México]]></addr-line>
<country>México</country>
</aff>
<aff id="A14">
<institution><![CDATA[,Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado Hospital Regional de Alta Especialidad Centenario de la Revolución Mexicana ]]></institution>
<addr-line><![CDATA[Morelos ]]></addr-line>
<country>México</country>
</aff>
<aff id="A15">
<institution><![CDATA[,Hospital Infantil de México Federico Gómez  ]]></institution>
<addr-line><![CDATA[ Ciudad de México]]></addr-line>
<country>México</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>00</month>
<year>2024</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>00</month>
<year>2024</year>
</pub-date>
<volume>94</volume>
<fpage>1</fpage>
<lpage>33</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S1405-99402024000700001&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S1405-99402024000700001&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S1405-99402024000700001&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen La amiloidosis es una enfermedad heterogénea, de origen hereditario o adquirido, que se caracteriza por el depósito anormal de proteínas fibrilares en diversos tejidos. Esta enfermedad puede manifestarse de manera localizada o sistémica, lo que genera una amplia variabilidad en su presentación clínica y, frecuentemente, retrasa el diagnóstico. Por ello, es fundamental la identificación temprana de los signos y síntomas para mejorar el pronóstico. El primer posicionamiento mexicano sobre la amiloidosis cardíaca tiene como objetivo resumir las principales características de la enfermedad y sus subtipos, identificando datos de alarma que incrementen la sospecha de su presencia. Además, busca ofrecer un algoritmo diagnóstico que integre los estudios de imagen y de laboratorio disponibles en nuestro país, con el fin de simplificar la toma de decisiones y llegar a un diagnóstico de manera rápida, práctica y actualizada, basado en recomendaciones sustentadas en evidencia científica. Una vez confirmado el diagnóstico, se abordan los distintos retos terapéuticos, tanto farmacológicos como no farmacológicos, ya que los pacientes no responden al tratamiento convencional de insuficiencia cardíaca. Por ello, el tratamiento debe ser individualizado para cada paciente, teniendo en cuenta la presencia de otras comorbilidades. Finalmente, se presentan los principales factores pronósticos que guiarán un tratamiento adecuado, incluyendo los resultados del asesoramiento genético.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract Amyloidosis is a heterogeneous, hereditary or acquired disease characterized by the abnormal deposition of fibrillar proteins in various tissues. The disease can be either localized or systemic, leading to significant variability in its clinical presentation and often causing diagnostic delays. For this reason, early identification of signs and symptoms is essential to improve prognosis. The first Mexican position paper on cardiac amyloidosis aims to summarize the main features of the disease and its subtypes, identifying warning signs that increase clinical suspicion. Additionally, it provides a diagnostic algorithm incorporating the imaging and laboratory studies available in our country, to streamline decision-making and facilitate a fast, practical, and up-to-date diagnosis based on evidence-based recommendations. Once the diagnosis is confirmed, the various therapeutic challenges of this disease, both pharmacological and non-pharmacological, are discussed, as patients do not respond to conventional heart failure treatments. Therefore, treatment must be individualized for each patient, considering the presence of other comorbidities. Finally, the key prognostic factors are outlined to guide appropriate treatment, including results from genetic counseling.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Amiloidosis]]></kwd>
<kwd lng="es"><![CDATA[Amiloidosis cardíaca]]></kwd>
<kwd lng="es"><![CDATA[Amiloidosis de inmunoglobulinas de cadenas ligeras]]></kwd>
<kwd lng="es"><![CDATA[Transtiretina]]></kwd>
<kwd lng="es"><![CDATA[Diagnóstico]]></kwd>
<kwd lng="es"><![CDATA[Pronóstico. Tratamiento]]></kwd>
<kwd lng="en"><![CDATA[Amyloidosis]]></kwd>
<kwd lng="en"><![CDATA[Cardiac amyloidosis]]></kwd>
<kwd lng="en"><![CDATA[inmunoglobulin light-chain amyloidosis]]></kwd>
<kwd lng="en"><![CDATA[Transthyretin]]></kwd>
<kwd lng="en"><![CDATA[Diagnosis]]></kwd>
<kwd lng="en"><![CDATA[Prognosis. Treatment]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Maurer]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[Elliott]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Comenzo]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Semigran]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Rapezzi]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Addressing common questions encountered in the diagnosis and management of cardiac amyloidosis]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2017</year>
<volume>135</volume>
<numero>14</numero>
<issue>14</issue>
<page-range>1357-77</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Correction to:Cardiac amyloidosis:Evolving diagnosis and management:A scientific statement from the American Heart Association]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2021</year>
<volume>144</volume>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gertz]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Dispenzieri]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Sher]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pathophysiology and treatment of cardiac amyloidosis]]></article-title>
<source><![CDATA[Nat Rev Cardiol]]></source>
<year>2015</year>
<volume>12</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>91-102</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Siddiqi]]></surname>
<given-names><![CDATA[OK]]></given-names>
</name>
<name>
<surname><![CDATA[Ruberg]]></surname>
<given-names><![CDATA[FL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cardiac amyloidosis:An update on pathophysiology, diagnosis, and treatment]]></article-title>
<source><![CDATA[Trends Cardiovasc Med]]></source>
<year>2018</year>
<volume>28</volume>
<numero>(1)</numero>
<issue>(1)</issue>
<page-range>10-21</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Maurer]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[Schwartz]]></surname>
<given-names><![CDATA[JH]]></given-names>
</name>
<name>
<surname><![CDATA[Gundapaneni]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Elliott]]></surname>
<given-names><![CDATA[PM]]></given-names>
</name>
<name>
<surname><![CDATA[Merlini]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Waddington-Cruz]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2018</year>
<volume>379</volume>
<numero>(11)</numero>
<issue>(11)</issue>
<page-range>1007-16</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kyle]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Larson]]></surname>
<given-names><![CDATA[DR]]></given-names>
</name>
<name>
<surname><![CDATA[Kurtin]]></surname>
<given-names><![CDATA[PJ]]></given-names>
</name>
<name>
<surname><![CDATA[Kumar]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Cerhan]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[Therneau]]></surname>
<given-names><![CDATA[TM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Incidence of AL Amyloidosis in Olmsted County, Minnesota, 1990 through 2015]]></article-title>
<source><![CDATA[Mayo Clin Proc]]></source>
<year>2019</year>
<volume>94</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>465-71</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Merlini]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Bellotti]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Molecular mechanisms of amyloidosis]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2003</year>
<volume>349</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>583-96</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Martinez-Naharro]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Hawkins]]></surname>
<given-names><![CDATA[PN]]></given-names>
</name>
<name>
<surname><![CDATA[Fontana]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cardiac amyloidosis]]></article-title>
<source><![CDATA[Clin Med (Lond)]]></source>
<year>2018</year>
<volume>18</volume>
<numero>(Suppl 2)</numero>
<issue>(Suppl 2)</issue>
<page-range>s30-5</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Montserrat Moliner]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Waligora]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The European Union policy in the field of rare diseases]]></article-title>
<source><![CDATA[Adv Exp Med Biol]]></source>
<year>2017</year>
<volume>1031</volume>
<page-range>561-87</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Aimo]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Merlo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Porcari]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Georgiopoulos]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Pagura]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Vergaro]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Redefining the epidemiology of cardiac amyloidosis. A systematic review and meta-analysis of screening studies]]></article-title>
<source><![CDATA[Eur J Heart Fail]]></source>
<year>2022</year>
<volume>24</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>2342-51</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ravichandran]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Lachmann]]></surname>
<given-names><![CDATA[HJ]]></given-names>
</name>
<name>
<surname><![CDATA[Wechalekar]]></surname>
<given-names><![CDATA[AD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Epidemiologic and survival trends in amyloidosis, 1987-2019]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2020</year>
<volume>382</volume>
<numero>(16)</numero>
<issue>(16)</issue>
<page-range>1564-7</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cruz]]></surname>
<given-names><![CDATA[MW]]></given-names>
</name>
<name>
<surname><![CDATA[Barroso]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[González-Duarte]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Mundayat]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Ong]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The demographic, genetic, and clinical characteristics of Latin American subjects enrolled in the Transthyretin Amyloidosis Outcomes Survey]]></article-title>
<source><![CDATA[Amyloid]]></source>
<year>2017</year>
<volume>24</volume>
<page-range>107-8</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[González-Duarte]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Cárdenas-Soto]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Bañuelos]]></surname>
<given-names><![CDATA[CE]]></given-names>
</name>
<name>
<surname><![CDATA[Fueyo]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Dominguez]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Torres]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Amyloidosis due to TTR mutations in Mexico with 4 distincts genotypes in the index cases]]></article-title>
<source><![CDATA[Orphanet J Rare Dis]]></source>
<year>2018</year>
<volume>13</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>107</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Arshad]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Goldberg]]></surname>
<given-names><![CDATA[YH]]></given-names>
</name>
<name>
<surname><![CDATA[Bhopalwala]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Dewaswala]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Miceli]]></surname>
<given-names><![CDATA[NS]]></given-names>
</name>
<name>
<surname><![CDATA[Birks]]></surname>
<given-names><![CDATA[EJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[High prevalence of cardiac amyloidosis in clinically significant aortic stenosis:a meta-analysis]]></article-title>
<source><![CDATA[Cardiol Res]]></source>
<year>2022</year>
<volume>13</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>357-71</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Magdi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Mostafa]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
<name>
<surname><![CDATA[Abusnina]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Al-abdouh]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Doss]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Mohamed]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A systematic review and meta-analysis of the prevalence of transthyretin amyloidosis in heart failure with preserved ejection fraction]]></article-title>
<source><![CDATA[Am J Cardiovasc Dis]]></source>
<year>2022</year>
<volume>12</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>102-11</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nils]]></surname>
<given-names><![CDATA[FK]]></given-names>
</name>
<name>
<surname><![CDATA[Ana]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Mahmoud]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Mark]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Rozenbaum]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Estimating the gender distribution of patients with wild-type transthyretin amyloid cardiomyopathy:a systematic review and meta-analysis]]></article-title>
<source><![CDATA[Cardiol Ther]]></source>
<year>2021</year>
<volume>10</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>41-55</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nativi-Nicolau]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Siu]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Dispenzieri]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Maurer]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[Rapezzi]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Kristen]]></surname>
<given-names><![CDATA[AV]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Temporal trends of wild-type transthyretin amyloid cardiomyopathy in the Transthyretin Amyloidosis Outcomes Survey]]></article-title>
<source><![CDATA[JACC CardioOncol]]></source>
<year>2021</year>
<volume>3</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>537-46</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pinney]]></surname>
<given-names><![CDATA[JH]]></given-names>
</name>
<name>
<surname><![CDATA[Whelan]]></surname>
<given-names><![CDATA[CJ]]></given-names>
</name>
<name>
<surname><![CDATA[Petrie]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Dungu]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Banypersad]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
<name>
<surname><![CDATA[Sattianayagam]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Senile systemic amyloidosis:clinical features at presentation and outcome]]></article-title>
<source><![CDATA[J Am Heart Assoc]]></source>
<year>2013</year>
<volume>2</volume>
<numero>2</numero>
<issue>2</issue>
</nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wechalekar]]></surname>
<given-names><![CDATA[AD]]></given-names>
</name>
<name>
<surname><![CDATA[Schonland]]></surname>
<given-names><![CDATA[SO]]></given-names>
</name>
<name>
<surname><![CDATA[Kastritis]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Gillmore]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
<name>
<surname><![CDATA[Dimopoulos]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Lane]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis]]></article-title>
<source><![CDATA[Blood]]></source>
<year>2013</year>
<volume>121</volume>
<numero>17</numero>
<issue>17</issue>
<page-range>3420-7</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vaxman]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Gertz]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[When to suspect a diagnosis of amyloidosis]]></article-title>
<source><![CDATA[Acta Haematol]]></source>
<year>2020</year>
<volume>143</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>304-11</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Papa]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Lachmann]]></surname>
<given-names><![CDATA[HJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Secondary, AA, amyloidosis]]></article-title>
<source><![CDATA[Rheum Dis Clin North Am]]></source>
<year>2018</year>
<volume>44</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>585-603</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lachmann]]></surname>
<given-names><![CDATA[HJ]]></given-names>
</name>
<name>
<surname><![CDATA[Goodman]]></surname>
<given-names><![CDATA[HJB]]></given-names>
</name>
<name>
<surname><![CDATA[Gilbertson]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Gallimore]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[Sabin]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Gillmore]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Natural history and outcome in systemic AA amyloidosis]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2007</year>
<volume>356</volume>
<numero>23</numero>
<issue>23</issue>
<page-range>2361-71</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sattianayagam]]></surname>
<given-names><![CDATA[PT]]></given-names>
</name>
<name>
<surname><![CDATA[Hawkins]]></surname>
<given-names><![CDATA[PN]]></given-names>
</name>
<name>
<surname><![CDATA[Gillmore]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Systemic amyloidosis and the gastrointestinal tract]]></article-title>
<source><![CDATA[Nat Rev Gastroenterol Hepatol]]></source>
<year>2009</year>
<volume>6</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>608-17</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fotiou]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Dimopoulos]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Kastritis]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Systemic AL amyloidosis:current approaches to diagnosis and management]]></article-title>
<source><![CDATA[Hemasphere]]></source>
<year>2020</year>
<volume>4</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>12</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hwa]]></surname>
<given-names><![CDATA[YL]]></given-names>
</name>
<name>
<surname><![CDATA[Fogaren]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Sams]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Faller]]></surname>
<given-names><![CDATA[DV]]></given-names>
</name>
<name>
<surname><![CDATA[Stull]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
<name>
<surname><![CDATA[Thuenemann]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Immunoglobulin light-chain amyloidosis:clinical presentations and diagnostic approach]]></article-title>
<source><![CDATA[J Adv Pract Oncol]]></source>
<year>2019</year>
<volume>10</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>470</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bird]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Guidelines on the diagnosis and management of AL amyloidosis]]></article-title>
<source><![CDATA[Br J Haematol]]></source>
<year>2004</year>
<volume>125</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>681-700</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Merlini]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Palladini]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Differential diagnosis of monoclonal gammopathy of undetermined significance]]></article-title>
<source><![CDATA[Hematology Am Soc Hematol Educ Program]]></source>
<year>2012</year>
<volume>2012</volume>
<page-range>595-603</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kittleson]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
<name>
<surname><![CDATA[Ruberg]]></surname>
<given-names><![CDATA[FL]]></given-names>
</name>
<name>
<surname><![CDATA[Ambardekar]]></surname>
<given-names><![CDATA[AV]]></given-names>
</name>
<name>
<surname><![CDATA[Brannagan]]></surname>
<given-names><![CDATA[TH]]></given-names>
</name>
<name>
<surname><![CDATA[Cheng]]></surname>
<given-names><![CDATA[RK]]></given-names>
</name>
<name>
<surname><![CDATA[Clarke]]></surname>
<given-names><![CDATA[JO]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[2023 ACC Expert Consensus Decision Pathway on Comprehensive Multidisciplinary Care for the Patient With Cardiac Amyloidosis:A Report of the American College of Cardiology Solution Set Oversight Committee]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>2023</year>
<volume>81</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1076-126</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nativi-Nicolau]]></surname>
<given-names><![CDATA[JN]]></given-names>
</name>
<name>
<surname><![CDATA[Karam]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Khella]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Maurer]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Screening for ATTR amyloidosis in the clinic:overlapping disorders, misdiagnosis, and multiorgan awareness]]></article-title>
<source><![CDATA[Heart Fail Rev]]></source>
<year>2022</year>
<volume>27</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>785-93</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tanskanen]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Peuralinna]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Polvikoski]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Notkola]]></surname>
<given-names><![CDATA[IL]]></given-names>
</name>
<name>
<surname><![CDATA[Sulkava]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Hardy]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau:A population-based autopsy study]]></article-title>
<source><![CDATA[Ann Med]]></source>
<year>2008</year>
<volume>40</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>232-9</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sperry]]></surname>
<given-names><![CDATA[BW]]></given-names>
</name>
<name>
<surname><![CDATA[Reyes]]></surname>
<given-names><![CDATA[BA]]></given-names>
</name>
<name>
<surname><![CDATA[Ikram]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Donnelly]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Phelan]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Jaber]]></surname>
<given-names><![CDATA[WA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tenosynovial and cardiac amyloidosis in patients undergoing carpal tunnel release]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>2018</year>
<volume>72</volume>
<numero>17</numero>
<issue>17</issue>
<page-range>2040-50</page-range></nlm-citation>
</ref>
<ref id="B32">
<label>32</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[González-López]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Gallego-Delgado]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Guzzo-Merello]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[De Haro-Del Moral]]></surname>
<given-names><![CDATA[FJ]]></given-names>
</name>
<name>
<surname><![CDATA[Cobo-Marcos]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Robles]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction]]></article-title>
<source><![CDATA[Eur Heart J]]></source>
<year>2015</year>
<volume>36</volume>
<numero>38</numero>
<issue>38</issue>
<page-range>2585-94</page-range></nlm-citation>
</ref>
<ref id="B33">
<label>33</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Treibel]]></surname>
<given-names><![CDATA[TA]]></given-names>
</name>
<name>
<surname><![CDATA[Fontana]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Gilbertson]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Castelletti]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[White]]></surname>
<given-names><![CDATA[SK]]></given-names>
</name>
<name>
<surname><![CDATA[Scully]]></surname>
<given-names><![CDATA[PR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Occult transthyretin cardiac amyloid in severe calcific aortic stenosis]]></article-title>
<source><![CDATA[Circ Cardiovasc Imaging]]></source>
<year>2016</year>
<volume>9</volume>
<numero>8</numero>
<issue>8</issue>
</nlm-citation>
</ref>
<ref id="B34">
<label>34</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Castanõ]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Bokhari]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Maurer]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Unveiling wild-type transthyretin cardiac amyloidosis as a significant and potentially modifiable cause of heart failure with preserved ejection fraction]]></article-title>
<source><![CDATA[Eur Heart J]]></source>
<year>2015</year>
<volume>36</volume>
<numero>38</numero>
<issue>38</issue>
<page-range>2595-7</page-range></nlm-citation>
</ref>
<ref id="B35">
<label>35</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Eldhagen]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Berg]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Lund]]></surname>
<given-names><![CDATA[LH]]></given-names>
</name>
<name>
<surname><![CDATA[Sörensson]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Suhr]]></surname>
<given-names><![CDATA[OB]]></given-names>
</name>
<name>
<surname><![CDATA[Westermark]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Transthyretin amyloid deposits in lumbar spinal stenosis and assessment of signs of systemic amyloidosis]]></article-title>
<source><![CDATA[J Intern Med]]></source>
<year>2021</year>
<volume>289</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>895-905</page-range></nlm-citation>
</ref>
<ref id="B36">
<label>36</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rapezzi]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Elliott]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Damy]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Nativi-Nicolau]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Berk]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Velazquez]]></surname>
<given-names><![CDATA[EJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy of tafamidis in patients with hereditary and wild-type transthyretin amyloid cardiomyopathy:further analyses from ATTR-ACT]]></article-title>
<source><![CDATA[JACC Heart Fail]]></source>
<year>2021</year>
<volume>9</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>115-23</page-range></nlm-citation>
</ref>
<ref id="B37">
<label>37</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Murtagh]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Hammill]]></surname>
<given-names><![CDATA[SC]]></given-names>
</name>
<name>
<surname><![CDATA[Gertz]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Kyle]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Tajik]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Grogan]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Electrocardiographic findings in primary systemic amyloidosis and biopsy-proven cardiac involvement]]></article-title>
<source><![CDATA[Am J Cardiol]]></source>
<year>2005</year>
<volume>95</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>535-7</page-range></nlm-citation>
</ref>
<ref id="B38">
<label>38</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cyrille]]></surname>
<given-names><![CDATA[NB]]></given-names>
</name>
<name>
<surname><![CDATA[Goldsmith]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Alvarez]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Maurer]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevalence and prognostic significance of low QRS voltage among the three main types of cardiac amyloidosis]]></article-title>
<source><![CDATA[Am J Cardiol]]></source>
<year>2014</year>
<volume>114</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>1089-93</page-range></nlm-citation>
</ref>
<ref id="B39">
<label>39</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Abstract 16852:A Simple Voltage/Mass Index Improves Diagnosis of Cardiac Amyloidosis in Patients With Unexplained Left Ventricular "Hypertrophy":An Electrocardiographic and Echocardiographic Study of More Than 500 Patients]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2010</year>
<volume>122</volume>
<numero>(Suppl. 21)</numero>
<issue>(Suppl. 21)</issue>
</nlm-citation>
</ref>
<ref id="B40">
<label>40</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rapezzi]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Merlini]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Quarta]]></surname>
<given-names><![CDATA[CC]]></given-names>
</name>
<name>
<surname><![CDATA[Riva]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Longhi]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Leone]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Systemic cardiac amyloidoses:Disease profiles and clinical courses of the 3 main types]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2009</year>
<volume>120</volume>
<numero>13</numero>
<issue>13</issue>
<page-range>1203-12</page-range></nlm-citation>
</ref>
<ref id="B41">
<label>41</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cheng]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Kang]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Tian]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Guo]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Xu]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Utility of combined indexes of electrocardiography and echocardiography in the diagnosis of biopsy proven primary cardiac amyloidosis]]></article-title>
<source><![CDATA[Ann Noninvasive Electrocardiol]]></source>
<year>2011</year>
<volume>16</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>25-9</page-range></nlm-citation>
</ref>
<ref id="B42">
<label>42</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yilmaz]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Bauersachs]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Bengel]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Büchel]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Kindermann]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Klingel]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diagnosis and treatment of cardiac amyloidosis:position statement of the German Cardiac Society (DGK)]]></article-title>
<source><![CDATA[Clin Res Cardiol]]></source>
<year>2021</year>
<volume>110</volume>
<numero>(4)</numero>
<issue>(4)</issue>
<page-range>479-506</page-range></nlm-citation>
</ref>
<ref id="B43">
<label>43</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sperry]]></surname>
<given-names><![CDATA[BW]]></given-names>
</name>
<name>
<surname><![CDATA[Vranian]]></surname>
<given-names><![CDATA[MN]]></given-names>
</name>
<name>
<surname><![CDATA[Hachamovitch]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Joshi]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[McCarthy]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Ikram]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Are classic predictors of voltage valid in cardiac amyloidosis?A contemporary analysis of electrocardiographic findings]]></article-title>
<source><![CDATA[Int J Cardiol]]></source>
<year>2016</year>
<volume>214</volume>
<page-range>477-81</page-range></nlm-citation>
</ref>
<ref id="B44">
<label>44</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cappelli]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Vignini]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Martone]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Perlini]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Mussinelli]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Sabena]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Baseline ECG features and arrhythmic profile in transthyretin versus light chain cardiac amyloidosis]]></article-title>
<source><![CDATA[Circ Heart Fail]]></source>
<year>2020</year>
<volume>13</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>E006619</page-range></nlm-citation>
</ref>
<ref id="B45">
<label>45</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cipriani]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[De Michieli]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Porcari]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Licchelli]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Sinigiani]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Tini]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Low QRS voltages in cardiac amyloidosis:clinical correlates and prognostic value]]></article-title>
<source><![CDATA[JACC CardioOncol]]></source>
<year>2022</year>
<volume>4</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>458-70</page-range></nlm-citation>
</ref>
<ref id="B46">
<label>46</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mussinelli]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Salinaro]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Alogna]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Boldrini]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Raimondi]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Musca]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diagnostic and prognostic value of low QRS voltages in cardiac AL amyloidosis]]></article-title>
<source><![CDATA[Ann Noninvasive Electrocardiol]]></source>
<year>2013</year>
<volume>18</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>271-80</page-range></nlm-citation>
</ref>
<ref id="B47">
<label>47</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kristen]]></surname>
<given-names><![CDATA[AV]]></given-names>
</name>
<name>
<surname><![CDATA[Perz]]></surname>
<given-names><![CDATA[JB]]></given-names>
</name>
<name>
<surname><![CDATA[Schonland]]></surname>
<given-names><![CDATA[SO]]></given-names>
</name>
<name>
<surname><![CDATA[Hegenbart]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Schnabel]]></surname>
<given-names><![CDATA[PA]]></given-names>
</name>
<name>
<surname><![CDATA[Kristen]]></surname>
<given-names><![CDATA[JH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Non-invasive predictors of survival in cardiac amyloidosis]]></article-title>
<source><![CDATA[Eur J Heart Fail]]></source>
<year>2007</year>
<volume>9</volume>
<numero>(6-7)</numero>
<issue>(6-7)</issue>
<page-range>617-24</page-range></nlm-citation>
</ref>
<ref id="B48">
<label>48</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Eriksson]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Karp]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Bjerle]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Olofsson]]></surname>
<given-names><![CDATA[BO]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Disturbances of cardiac rhythm and conduction in familial amyloidosis with polyneuropathy]]></article-title>
<source><![CDATA[Heart]]></source>
<year>1984</year>
<volume>51</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>658-62</page-range></nlm-citation>
</ref>
<ref id="B49">
<label>49</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[González-López]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Gagliardi]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Dominguez]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Quarta]]></surname>
<given-names><![CDATA[CC]]></given-names>
</name>
<name>
<surname><![CDATA[De Haro-Del Moral]]></surname>
<given-names><![CDATA[FJ]]></given-names>
</name>
<name>
<surname><![CDATA[Milandri]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical characteristics of wild-type transthyretin cardiac amyloidosis:disproving myths]]></article-title>
<source><![CDATA[Eur Heart J]]></source>
<year>2017</year>
<volume>38</volume>
<numero>(24)</numero>
<issue>(24)</issue>
<page-range>1895-904</page-range></nlm-citation>
</ref>
<ref id="B50">
<label>50</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hartnett]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Jaber]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Maurer]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Sperry]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Hanna]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Collier]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Electrophysiological manifestations of cardiac amyloidosis:JACC:CardioOncology State-of-the-Art Review]]></article-title>
<source><![CDATA[JACC CardioOncol]]></source>
<year>2021</year>
<volume>3</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>506-15</page-range></nlm-citation>
</ref>
<ref id="B51">
<label>51</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Reisinger]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Dubrey]]></surname>
<given-names><![CDATA[SW]]></given-names>
</name>
<name>
<surname><![CDATA[Lavalley]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Skinner]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Falk]]></surname>
<given-names><![CDATA[RH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Electrophysiologic abnormalities in AL (primary) amyloidosis with cardiac involvement]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>1997</year>
<volume>30</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>1046-51</page-range></nlm-citation>
</ref>
<ref id="B52">
<label>52</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dubrey]]></surname>
<given-names><![CDATA[SW]]></given-names>
</name>
<name>
<surname><![CDATA[Cha]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Anderson]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Chamarthi]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Reisinger]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Skinner]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement]]></article-title>
<source><![CDATA[QJM]]></source>
<year>1998</year>
<volume>91</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>141-57</page-range></nlm-citation>
</ref>
<ref id="B53">
<label>53</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Goldsmith]]></surname>
<given-names><![CDATA[YB]]></given-names>
</name>
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Chou]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Hoffman]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Comenzo]]></surname>
<given-names><![CDATA[RL]]></given-names>
</name>
<name>
<surname><![CDATA[Steingart]]></surname>
<given-names><![CDATA[RM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Frequencies and types of arrhythmias in patients with systemic light-chain amyloidosis with cardiac involvement undergoing stem cell transplantation on telemetry monitoring]]></article-title>
<source><![CDATA[Am J Cardiol]]></source>
<year>2009</year>
<volume>104</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>990-4</page-range></nlm-citation>
</ref>
<ref id="B54">
<label>54</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sharma]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Labib]]></surname>
<given-names><![CDATA[SB]]></given-names>
</name>
<name>
<surname><![CDATA[Shah]]></surname>
<given-names><![CDATA[SP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Electrocardiogram criteria to diagnose cardiac amyloidosis in men with a bundle branch block]]></article-title>
<source><![CDATA[Am J Cardiol]]></source>
<year>2021</year>
<volume>146</volume>
<page-range>89-94</page-range></nlm-citation>
</ref>
<ref id="B55">
<label>55</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Alreshq]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Tugal]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Siddiqi]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Ruberg]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Conduction abnormalities and role of cardiac pacing in cardiac amyloidosis:A systematic review]]></article-title>
<source><![CDATA[Pacing Clin Electrophysiol]]></source>
<year>2021</year>
<volume>44</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>2092-9</page-range></nlm-citation>
</ref>
<ref id="B56">
<label>56</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Barbhaiya]]></surname>
<given-names><![CDATA[CR]]></given-names>
</name>
<name>
<surname><![CDATA[Kumar]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Baldinger]]></surname>
<given-names><![CDATA[SH]]></given-names>
</name>
<name>
<surname><![CDATA[Michaud]]></surname>
<given-names><![CDATA[GF]]></given-names>
</name>
<name>
<surname><![CDATA[Stevenson]]></surname>
<given-names><![CDATA[WG]]></given-names>
</name>
<name>
<surname><![CDATA[Falk]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Electrophysiologic assessment of conduction abnormalities and atrial arrhythmias associated with amyloid cardiomyopathy]]></article-title>
<source><![CDATA[Heart Rhythm]]></source>
<year>2016</year>
<volume>13</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>383-90</page-range></nlm-citation>
</ref>
<ref id="B57">
<label>57</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Namdar]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Steffel]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Jetzer]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Schmied]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Hrlimann]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Camici]]></surname>
<given-names><![CDATA[GG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Value of electrocardiogram in the differentiation of hypertensive heart disease, hypertrophic cardiomyopathy, aortic stenosis, amyloidosis, and fabry disease]]></article-title>
<source><![CDATA[Am J Cardiol]]></source>
<year>2012</year>
<volume>109</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>587-93</page-range></nlm-citation>
</ref>
<ref id="B58">
<label>58</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Banypersad]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
<name>
<surname><![CDATA[Fontana]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Maestrini]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Sado]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
<name>
<surname><![CDATA[Captur]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Petrie]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[T1 mapping and survival in systemic light-chain amyloidosis]]></article-title>
<source><![CDATA[Eur Heart J]]></source>
<year>2015</year>
<volume>36</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>244-51</page-range></nlm-citation>
</ref>
<ref id="B59">
<label>59</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Phelan]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Collier]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Thavendiranathan]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Popovi&#263;]]></surname>
<given-names><![CDATA[ZB]]></given-names>
</name>
<name>
<surname><![CDATA[Hanna]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Plana]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis]]></article-title>
<source><![CDATA[Heart]]></source>
<year>2012</year>
<volume>98</volume>
<numero>19</numero>
<issue>19</issue>
<page-range>1442-8</page-range></nlm-citation>
</ref>
<ref id="B60">
<label>60</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[SP]]></given-names>
</name>
<name>
<surname><![CDATA[Park]]></surname>
<given-names><![CDATA[JB]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[HK]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[YJ]]></given-names>
</name>
<name>
<surname><![CDATA[Grogan]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Sohn]]></surname>
<given-names><![CDATA[DW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Contemporary imaging diagnosis of cardiac amyloidosis]]></article-title>
<source><![CDATA[J Cardiovasc Imaging]]></source>
<year>2019</year>
<volume>27</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1-10</page-range></nlm-citation>
</ref>
<ref id="B61">
<label>61</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Roger-Rollé]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Cariou]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Rguez]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Fournier]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Lavie-Badie]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Blanchard]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Can myocardial work indices contribute to the exploration of patients with cardiac amyloidosis?]]></article-title>
<source><![CDATA[Open Heart]]></source>
<year>2020</year>
<volume>7</volume>
<numero>2</numero>
<issue>2</issue>
</nlm-citation>
</ref>
<ref id="B62">
<label>62</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Palmiero]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Rubino]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Monda]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Caiazza]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[D'urso]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Carlomagno]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Global left ventricular myocardial work efficiency in heart failure patients with cardiac amyloidosis:pathophysiological implications and role in differential diagnosis]]></article-title>
<source><![CDATA[J Cardiovasc Echogr]]></source>
<year>2021</year>
<volume>31</volume>
<numero>(3)</numero>
<issue>(3)</issue>
<page-range>157</page-range></nlm-citation>
</ref>
<ref id="B63">
<label>63</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dorbala]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Ando]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Bokhari]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Dispenzieri]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Falk]]></surname>
<given-names><![CDATA[RH]]></given-names>
</name>
<name>
<surname><![CDATA[Ferrari]]></surname>
<given-names><![CDATA[VA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert consensus recommendations for multimodality imaging in cardiac amyloidosis:Part 1 of 2 - Evidence base and standardized methods of imaging]]></article-title>
<source><![CDATA[Circ Cardiovasc Imaging]]></source>
<year>2021</year>
<volume>14</volume>
<numero>7</numero>
<issue>7</issue>
</nlm-citation>
</ref>
<ref id="B64">
<label>64</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zhao]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Tian]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Fang]]></surname>
<given-names><![CDATA[Q]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diagnostic accuracy of cardiovascular magnetic resonance for patients with suspected cardiac amyloidosis:A systematic review and meta-analysis]]></article-title>
<source><![CDATA[BMC Cardiovasc Disord]]></source>
<year>2016</year>
<volume>16</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1-10</page-range></nlm-citation>
</ref>
<ref id="B65">
<label>65</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Syed]]></surname>
<given-names><![CDATA[IS]]></given-names>
</name>
<name>
<surname><![CDATA[Glockner]]></surname>
<given-names><![CDATA[JF]]></given-names>
</name>
<name>
<surname><![CDATA[Feng]]></surname>
<given-names><![CDATA[DL]]></given-names>
</name>
<name>
<surname><![CDATA[Araoz]]></surname>
<given-names><![CDATA[PA]]></given-names>
</name>
<name>
<surname><![CDATA[Martinez]]></surname>
<given-names><![CDATA[MW]]></given-names>
</name>
<name>
<surname><![CDATA[Edwards]]></surname>
<given-names><![CDATA[WD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis]]></article-title>
<source><![CDATA[JACC Cardiovasc Imaging]]></source>
<year>2010</year>
<volume>3</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>155-64</page-range></nlm-citation>
</ref>
<ref id="B66">
<label>66</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Carvalho]]></surname>
<given-names><![CDATA[FP de]]></given-names>
</name>
<name>
<surname><![CDATA[Erthal]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Azevedo]]></surname>
<given-names><![CDATA[CF]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The role of cardiac MR imaging in the assessment of patients with cardiac amyloidosis]]></article-title>
<source><![CDATA[Magn Reson Imaging Clin N Am]]></source>
<year>2019</year>
<volume>27</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>453-63</page-range></nlm-citation>
</ref>
<ref id="B67">
<label>67</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yamaguchi]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Oda]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Kidoh]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Hayashi]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Takashio]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Usuku]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cardiac MRI T1 and T2 mapping as a quantitative imaging biomarker in transthyretin amyloid cardiomyopathy]]></article-title>
<source><![CDATA[Acad Radiol]]></source>
<year>2024</year>
<volume>31</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>514-22</page-range></nlm-citation>
</ref>
<ref id="B68">
<label>68</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Martinez-Naharro]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Treibel]]></surname>
<given-names><![CDATA[TA]]></given-names>
</name>
<name>
<surname><![CDATA[Abdel-Gadir]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Bulluck]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Zumbo]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Knight]]></surname>
<given-names><![CDATA[DS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Magnetic resonance in transthyretin cardiac amyloidosis]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>2017</year>
<volume>70</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>466-77</page-range></nlm-citation>
</ref>
<ref id="B69">
<label>69</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dorbala]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Ando]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Bokhari]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Dispenzieri]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Falk]]></surname>
<given-names><![CDATA[RH]]></given-names>
</name>
<name>
<surname><![CDATA[Ferrari]]></surname>
<given-names><![CDATA[VA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis:Part 2 of 2&#8211;Evidence base and standardized methods of imaging]]></article-title>
<source><![CDATA[J Nuclear Cardiol]]></source>
<year>2019</year>
<volume>26</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>2065-123</page-range></nlm-citation>
</ref>
<ref id="B70">
<label>70</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dorbala]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Ando]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Bokhari]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Dispenzieri]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Falk]]></surname>
<given-names><![CDATA[RH]]></given-names>
</name>
<name>
<surname><![CDATA[Ferrari]]></surname>
<given-names><![CDATA[VA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Addendum to ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis:Part 1 of 2-evidence base and standardized methods of imaging]]></article-title>
<source><![CDATA[J Nucl Cardiol]]></source>
<year>2021</year>
<volume>28</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>1769-74</page-range></nlm-citation>
</ref>
<ref id="B71">
<label>71</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Maurer]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[Bokhari]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Damy]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Dorbala]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Drachman]]></surname>
<given-names><![CDATA[BM]]></given-names>
</name>
<name>
<surname><![CDATA[Fontana]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Expert consensus recommendations for the suspicion and diagnosis of transthyretin cardiac amyloidosis]]></article-title>
<source><![CDATA[Circ Heart Fail]]></source>
<year>2019</year>
<volume>12</volume>
<numero>(9)</numero>
<issue>(9)</issue>
</nlm-citation>
</ref>
<ref id="B72">
<label>72</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Waheed]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Dorbala]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Current status of radionuclide imaging of transthyretin cardiac amyloidosis]]></article-title>
<source><![CDATA[Cardiol Clin]]></source>
<year>2023</year>
<volume>41</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>217-31</page-range></nlm-citation>
</ref>
<ref id="B73">
<label>73</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Meristoudis]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Ilias]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Keramida]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Potential diagnostic pitfalls of bone scintigraphy in transthyretin-related amyloidosis]]></article-title>
<source><![CDATA[World J Nucl Med]]></source>
<year>2020</year>
<volume>19</volume>
<numero>03</numero>
<issue>03</issue>
<page-range>313-4</page-range></nlm-citation>
</ref>
<ref id="B74">
<label>74</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Saad]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Ahmed]]></surname>
<given-names><![CDATA[AI]]></given-names>
</name>
<name>
<surname><![CDATA[Han]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Saeed]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Pournazari]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Al-Mallah]]></surname>
<given-names><![CDATA[MH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[99mTechnetium-labeled cardiac scintigraphy for suspected amyloidosis:a review of current and future directions]]></article-title>
<source><![CDATA[Heart Fail Rev]]></source>
<year>2022</year>
<volume>27</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>1493-503</page-range></nlm-citation>
</ref>
<ref id="B75">
<label>75</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Embry-Dierson]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Farrell]]></surname>
<given-names><![CDATA[MB]]></given-names>
</name>
<name>
<surname><![CDATA[Schockling]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Warren]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Jerome]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cardiac amyloidosis imaging, Part 1:amyloidosis etiology and image acquisition]]></article-title>
<source><![CDATA[J Nucl Med Technol]]></source>
<year>2023</year>
<volume>51</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>83-9</page-range></nlm-citation>
</ref>
<ref id="B76">
<label>76</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schockling]]></surname>
<given-names><![CDATA[EJ]]></given-names>
</name>
<name>
<surname><![CDATA[Farrell]]></surname>
<given-names><![CDATA[MB]]></given-names>
</name>
<name>
<surname><![CDATA[Embry-Dierson]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Warren]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Jerome]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cardiac amyloidosis imaging, Part 2:quantification and technical considerations]]></article-title>
<source><![CDATA[J Nucl Med Technol]]></source>
<year>2023</year>
<volume>51</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>90-8</page-range></nlm-citation>
</ref>
<ref id="B77">
<label>77</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dorbala]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Cuddy]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Falk]]></surname>
<given-names><![CDATA[RH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[How to image cardiac amyloidosis:a practical approach]]></article-title>
<source><![CDATA[JACC Cardiovasc Imaging]]></source>
<year>2020</year>
<volume>13</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1368-83</page-range></nlm-citation>
</ref>
<ref id="B78">
<label>78</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jerome]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Farrell]]></surname>
<given-names><![CDATA[MB]]></given-names>
</name>
<name>
<surname><![CDATA[Warren]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Embry-Dierson]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Schockling]]></surname>
<given-names><![CDATA[EJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cardiac amyloidosis imaging, Part 3:interpretation, diagnosis, and treatment]]></article-title>
<source><![CDATA[J Nucl Med Technol]]></source>
<year>2023</year>
<volume>51</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>102-16</page-range></nlm-citation>
</ref>
<ref id="B79">
<label>79</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Joseph]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Julien]]></surname>
<given-names><![CDATA[HM]]></given-names>
</name>
<name>
<surname><![CDATA[Bravo]]></surname>
<given-names><![CDATA[PE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Radionuclide imaging of cardiac amyloidosis]]></article-title>
<source><![CDATA[PET Clin]]></source>
<year>2021</year>
<volume>16</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>285-93</page-range></nlm-citation>
</ref>
<ref id="B80">
<label>80</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Khor]]></surname>
<given-names><![CDATA[YM]]></given-names>
</name>
<name>
<surname><![CDATA[Cuddy]]></surname>
<given-names><![CDATA[SAM]]></given-names>
</name>
<name>
<surname><![CDATA[Singh]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Falk]]></surname>
<given-names><![CDATA[RH]]></given-names>
</name>
<name>
<surname><![CDATA[Di Carli]]></surname>
<given-names><![CDATA[MF]]></given-names>
</name>
<name>
<surname><![CDATA[Dorbala]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[99mTc bone-avid tracer cardiac scintigraphy:role in noninvasive diagnosis of transthyretin cardiac amiloidosis]]></article-title>
<source><![CDATA[Radiology]]></source>
<year>2023</year>
<volume>306</volume>
<numero>2</numero>
<issue>2</issue>
</nlm-citation>
</ref>
<ref id="B81">
<label>81</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Poterucha]]></surname>
<given-names><![CDATA[TJ]]></given-names>
</name>
<name>
<surname><![CDATA[Elias]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Bokhari]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Einstein]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[DeLuca]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Kinkhabwala]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diagnosing transthyretin cardiac amyloidosis by technetium Tc 99m pyrophosphate:a test in evolution]]></article-title>
<source><![CDATA[JACC Cardiovasc Imaging]]></source>
<year>2021</year>
<volume>14</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1221-31</page-range></nlm-citation>
</ref>
<ref id="B82">
<label>82</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Garcia-Pavia]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Rapezzi]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Adler]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Arad]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Basso]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Brucato]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diagnosis and treatment of cardiac amyloidosis:A position statement of the ESC Working Group on Myocardial and Pericardial Diseases]]></article-title>
<source><![CDATA[Eur Heart J]]></source>
<year>2021</year>
<volume>42</volume>
<numero>16</numero>
<issue>16</issue>
<page-range>1554-68</page-range></nlm-citation>
</ref>
<ref id="B83">
<label>83</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brito]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Albrecht]]></surname>
<given-names><![CDATA[FC]]></given-names>
</name>
<name>
<surname><![CDATA[De Arenaza]]></surname>
<given-names><![CDATA[DP]]></given-names>
</name>
<name>
<surname><![CDATA[Bart]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Better]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Carvajal-Juarez]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[World Heart Federation Consensus on Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)]]></article-title>
<source><![CDATA[Glob Heart]]></source>
<year>2023</year>
<volume>18</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>59</page-range></nlm-citation>
</ref>
<ref id="B84">
<label>84</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gillmore]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
<name>
<surname><![CDATA[Maurer]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[Falk]]></surname>
<given-names><![CDATA[RH]]></given-names>
</name>
<name>
<surname><![CDATA[Merlini]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Damy]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Dispenzieri]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Nonbiopsy diagnosis of cardiac transthyretin amyloidosis]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2016</year>
<volume>133</volume>
<numero>24</numero>
<issue>24</issue>
<page-range>2404-12</page-range></nlm-citation>
</ref>
<ref id="B85">
<label>85</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Witteles]]></surname>
<given-names><![CDATA[RM]]></given-names>
</name>
<name>
<surname><![CDATA[Bokhari]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Damy]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Elliott]]></surname>
<given-names><![CDATA[PM]]></given-names>
</name>
<name>
<surname><![CDATA[Falk]]></surname>
<given-names><![CDATA[RH]]></given-names>
</name>
<name>
<surname><![CDATA[Fine]]></surname>
<given-names><![CDATA[NM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Screening for Transthyretin Amyloid Cardiomyopathy in Everyday Practice]]></article-title>
<source><![CDATA[JACC Heart Fail]]></source>
<year>2019</year>
<volume>7</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>709-16</page-range></nlm-citation>
</ref>
<ref id="B86">
<label>86</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[CC]]></given-names>
</name>
<name>
<surname><![CDATA[Chang]]></surname>
<given-names><![CDATA[WT]]></given-names>
</name>
<name>
<surname><![CDATA[Lin]]></surname>
<given-names><![CDATA[YH]]></given-names>
</name>
<name>
<surname><![CDATA[Tzeng]]></surname>
<given-names><![CDATA[BH]]></given-names>
</name>
<name>
<surname><![CDATA[Chao]]></surname>
<given-names><![CDATA[TH]]></given-names>
</name>
<name>
<surname><![CDATA[Hung]]></surname>
<given-names><![CDATA[CL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[2023 Expert Consensus of the Taiwan Society of Cardiology on the Diagnosis and Treatment of Cardiac Amyloidosis]]></article-title>
<source><![CDATA[Acta Cardiol Sin]]></source>
<year>2023</year>
<volume>39</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>511-43</page-range></nlm-citation>
</ref>
<ref id="B87">
<label>87</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Papathanasiou]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Carpinteiro]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Rischpler]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Hagenacker]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Rassaf]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Luedike]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diagnosing cardiac amyloidosis in every-day practice:A practical guide for the cardiologist]]></article-title>
<source><![CDATA[Int J Cardiol Heart Vasc]]></source>
<year>2020</year>
<volume>28</volume>
<page-range>100519</page-range></nlm-citation>
</ref>
<ref id="B88">
<label>88</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Savarese]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Becher]]></surname>
<given-names><![CDATA[PM]]></given-names>
</name>
<name>
<surname><![CDATA[Lund]]></surname>
<given-names><![CDATA[LH]]></given-names>
</name>
<name>
<surname><![CDATA[Seferovic]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Rosano]]></surname>
<given-names><![CDATA[GMC]]></given-names>
</name>
<name>
<surname><![CDATA[Coats]]></surname>
<given-names><![CDATA[AJS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Global burden of heart failure:a comprehensive and updated review of epidemiology]]></article-title>
<source><![CDATA[Cardiovasc Res]]></source>
<year>2023</year>
<volume>118</volume>
<numero>17</numero>
<issue>17</issue>
<page-range>3272-87</page-range></nlm-citation>
</ref>
<ref id="B89">
<label>89</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ruiz-Hueso]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Salamanca-Bautista]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Quesada-Simón]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Yun]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Conde-Martel]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Morales-Rull]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Estimating the prevalence of cardiac amyloidosis in old patients with heart failure&#8211;barriers and opportunities for improvement:the PREVAMIC study]]></article-title>
<source><![CDATA[J Clin Med]]></source>
<year>2023</year>
<volume>12</volume>
<numero>(6)</numero>
<issue>(6)</issue>
</nlm-citation>
</ref>
<ref id="B90">
<label>90</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gilstrap]]></surname>
<given-names><![CDATA[LG]]></given-names>
</name>
<name>
<surname><![CDATA[Dominici]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[El-Sady]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[Singh]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Di Carli]]></surname>
<given-names><![CDATA[MF]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Epidemiology of cardiac amyloidosis-associated heart failure hospitalizations among fee-for-service medicare beneficiaries in the United States]]></article-title>
<source><![CDATA[Circ Heart Fail]]></source>
<year>2019</year>
<volume>12</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>2273</page-range></nlm-citation>
</ref>
<ref id="B91">
<label>91</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Banypersad]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
<name>
<surname><![CDATA[Moon]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Whelan]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Hawkins]]></surname>
<given-names><![CDATA[PN]]></given-names>
</name>
<name>
<surname><![CDATA[Wechalekar]]></surname>
<given-names><![CDATA[AD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Updates in cardiac amyloidosis:A review]]></article-title>
<source><![CDATA[J Am Heart Assoc]]></source>
<year>2012</year>
<volume>1</volume>
<numero>(2)</numero>
<issue>(2)</issue>
</nlm-citation>
</ref>
<ref id="B92">
<label>92</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Griffin]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Maurer]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Transthyretin cardiac amyloidosis:A treatable form of heart failure with a preserved ejection fraction]]></article-title>
<source><![CDATA[Trends Cardiovasc Med]]></source>
<year>2021</year>
<volume>31</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>59-66</page-range></nlm-citation>
</ref>
<ref id="B93">
<label>93</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dobner]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Bernhard]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Asatryan]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Windecker]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Stortecky]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Pilgrim]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[SGLT2 inhibitor therapy for transthyretin amyloid cardiomyopathy:early tolerance and clinical response to dapagliflozin]]></article-title>
<source><![CDATA[ESC Heart Fail]]></source>
<year>2023</year>
<volume>10</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>397-404</page-range></nlm-citation>
</ref>
<ref id="B94">
<label>94</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Porcari]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Cappelli]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Nitsche]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Tomasoni]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Sinigiani]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Longhi]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[SGLT2 inhibitor therapy in patients with transthyretin amyloid cardiomyopathy]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>2024</year>
<volume>83</volume>
<numero>24</numero>
<issue>24</issue>
<page-range>2411-22</page-range></nlm-citation>
</ref>
<ref id="B95">
<label>95</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Donnelly]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Hanna]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cardiac amyloidosis:An update on diagnosis and treatment]]></article-title>
<source><![CDATA[Cleve Clin J Med]]></source>
<year>2017</year>
<volume>84</volume>
<page-range>12-26</page-range></nlm-citation>
</ref>
<ref id="B96">
<label>96</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Griffin]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Rosenthal]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Grodin]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Maurer]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[Grogan]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Cheng]]></surname>
<given-names><![CDATA[RK]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[ATTR amyloidosis:Current and emerging management strategies]]></article-title>
<source><![CDATA[JACC CardioOncol]]></source>
<year>2021</year>
<volume>3</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>488-505</page-range></nlm-citation>
</ref>
<ref id="B97">
<label>97</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Giancaterino]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Urey]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Darden]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Hsu]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Management of arrhythmias in cardiac amyloidosis]]></article-title>
<source><![CDATA[JACC Clin Electrophysiol]]></source>
<year>2020</year>
<volume>6</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>351-61</page-range></nlm-citation>
</ref>
<ref id="B98">
<label>98</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Feng]]></surname>
<given-names><![CDATA[DL]]></given-names>
</name>
<name>
<surname><![CDATA[Syed]]></surname>
<given-names><![CDATA[IS]]></given-names>
</name>
<name>
<surname><![CDATA[Martinez]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Oh]]></surname>
<given-names><![CDATA[JK]]></given-names>
</name>
<name>
<surname><![CDATA[Jaffe]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
<name>
<surname><![CDATA[Grogan]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Intracardiac thrombosis and anticoagulation therapy in cardiac amyloidosis]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2009</year>
<volume>119</volume>
<numero>18</numero>
<issue>18</issue>
<page-range>2490-7</page-range></nlm-citation>
</ref>
<ref id="B99">
<label>99</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dubrey]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Pollak]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Skinner]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Falk]]></surname>
<given-names><![CDATA[RH]]></given-names>
</name>
<name>
<surname><![CDATA[Falk]]></surname>
<given-names><![CDATA[RH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Atrial thrombi occurring during sinus rhythm in cardiac amyloidosis:evidence for atrial electromechanical dissociation]]></article-title>
<source><![CDATA[Br Heart J]]></source>
<year>1995</year>
<volume>74</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>541-4</page-range></nlm-citation>
</ref>
<ref id="B100">
<label>100</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bukhari]]></surname>
<given-names><![CDATA[Syed]]></given-names>
</name>
<name>
<surname><![CDATA[Khan]]></surname>
<given-names><![CDATA[Sz]]></given-names>
</name>
<name>
<surname><![CDATA[Bashir]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Atrial fibrillation, thromboembolic risk, and anticoagulation in cardiac amyloidosis:a review]]></article-title>
<source><![CDATA[J Card Fail]]></source>
<year>2023</year>
<volume>29</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>76-86</page-range></nlm-citation>
</ref>
<ref id="B101">
<label>101</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Donnellan]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Wazni]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Kanj]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Elshazly]]></surname>
<given-names><![CDATA[MB]]></given-names>
</name>
<name>
<surname><![CDATA[Hussein]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Baranowski]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Atrial fibrillation ablation in patients with transthyretin cardiac amyloidosis]]></article-title>
<source><![CDATA[Europace]]></source>
<year>2020</year>
<volume>22</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>259-64</page-range></nlm-citation>
</ref>
<ref id="B102">
<label>102</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vilches]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Fontana]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Gonzalez-Lopez]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Mitrani]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Saturi]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Renju]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Systemic embolism in amyloid transthyretin cardiomyopathy]]></article-title>
<source><![CDATA[Eur J Heart Fail]]></source>
<year>2022</year>
<volume>24</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>1387-96</page-range></nlm-citation>
</ref>
<ref id="B103">
<label>103</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bukhari]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Barakat]]></surname>
<given-names><![CDATA[AF]]></given-names>
</name>
<name>
<surname><![CDATA[Eisele]]></surname>
<given-names><![CDATA[YS]]></given-names>
</name>
<name>
<surname><![CDATA[Nieves]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Jain]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Saba]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevalence of atrial fibrillation and thromboembolic risk in wild-type transthyretin amyloid cardiomyopathy]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2021</year>
<volume>143</volume>
<numero>13</numero>
<issue>13</issue>
<page-range>1335-7</page-range></nlm-citation>
</ref>
<ref id="B104">
<label>104</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cappelli]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Tini]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Russo]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Emdin]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Del Franco]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Vergaro]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Arterial thrombo-embolic events in cardiac amyloidosis:a look beyond atrial fibrillation]]></article-title>
<source><![CDATA[Amyloid]]></source>
<year>2021</year>
<volume>28</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>12-8</page-range></nlm-citation>
</ref>
<ref id="B105">
<label>105</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Heidenreich]]></surname>
<given-names><![CDATA[PA]]></given-names>
</name>
<name>
<surname><![CDATA[Bozkurt]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Aguilar]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Allen]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
<name>
<surname><![CDATA[Byun]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Colvin]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure:A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2022</year>
<volume>145</volume>
<numero>18</numero>
<issue>18</issue>
<page-range>e1032</page-range></nlm-citation>
</ref>
<ref id="B106">
<label>106</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mitrani]]></surname>
<given-names><![CDATA[LR]]></given-names>
</name>
<name>
<surname><![CDATA[De Los Santos]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Driggin]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Kogan]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Helmke]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Goldsmith]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Anticoagulation with warfarin compared to novel oral anticoagulants for atrial fibrillation in adults with transthyretin cardiac amyloidosis:comparison of thromboembolic events and major bleeding]]></article-title>
<source><![CDATA[Amyloid]]></source>
<year>2021</year>
<volume>28</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>30-4</page-range></nlm-citation>
</ref>
<ref id="B107">
<label>107</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Laptseva]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Rossi]]></surname>
<given-names><![CDATA[VA]]></given-names>
</name>
<name>
<surname><![CDATA[Sudano]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Schwotzer]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Ruschitzka]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Flammer]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Arrhythmic manifestations of cardiac amyloidosis:challenges in risk stratification and clinical management]]></article-title>
<source><![CDATA[J Clin Med]]></source>
<year>2023</year>
<volume>12</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>2581</page-range></nlm-citation>
</ref>
<ref id="B108">
<label>108</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[EJ]]></given-names>
</name>
<name>
<surname><![CDATA[Holmes]]></surname>
<given-names><![CDATA[BB]]></given-names>
</name>
<name>
<surname><![CDATA[Huang]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Lugo]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Aboud]]></surname>
<given-names><![CDATA[A Al]]></given-names>
</name>
<name>
<surname><![CDATA[Goodman]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Outcomes in patients with cardiac amyloidosis and implantable cardioverter-defibrillator]]></article-title>
<source><![CDATA[Europace]]></source>
<year>2020</year>
<volume>22</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>1216-23</page-range></nlm-citation>
</ref>
<ref id="B109">
<label>109</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[John]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Arrhythmias in cardiac amyloidosis]]></article-title>
<source><![CDATA[J Innov Card Rhythm Manag]]></source>
<year>2018</year>
<volume>9</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>3051-7</page-range></nlm-citation>
</ref>
<ref id="B110">
<label>110</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Al-Khatib]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
<name>
<surname><![CDATA[Stevenson]]></surname>
<given-names><![CDATA[WG]]></given-names>
</name>
<name>
<surname><![CDATA[Ackerman]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Bryant]]></surname>
<given-names><![CDATA[WJ]]></given-names>
</name>
<name>
<surname><![CDATA[Callans]]></surname>
<given-names><![CDATA[DJ]]></given-names>
</name>
<name>
<surname><![CDATA[Curtis]]></surname>
<given-names><![CDATA[AB]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death:Executive Summary]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2018</year>
<volume>138</volume>
<numero>13</numero>
<issue>13</issue>
<page-range>71</page-range></nlm-citation>
</ref>
<ref id="B111">
<label>111</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Arbelo]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Protonotarios]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Gimeno]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[Arbustini]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Arbelo]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Barriales-Villa]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[2023 ESC Guidelines for the management of cardiomyopathies:Developed by the task force on the management of cardiomyopathies of the European Society of Cardiology (ESC)]]></article-title>
<source><![CDATA[Eur Heart J]]></source>
<year>2023</year>
<volume>44</volume>
<numero>37</numero>
<issue>37</issue>
<page-range>3503-626</page-range></nlm-citation>
</ref>
<ref id="B112">
<label>112</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zeppenfeld]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Tfelt-Hansen]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[De Riva]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Winkel]]></surname>
<given-names><![CDATA[BG]]></given-names>
</name>
<name>
<surname><![CDATA[Behr]]></surname>
<given-names><![CDATA[ER]]></given-names>
</name>
<name>
<surname><![CDATA[Blom]]></surname>
<given-names><![CDATA[NA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death]]></article-title>
<source><![CDATA[Eur Heart J]]></source>
<year>2022</year>
<volume>43</volume>
<numero>40</numero>
<issue>40</issue>
<page-range>3997-4126</page-range></nlm-citation>
</ref>
<ref id="B113">
<label>113</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Glikson]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Nielsen]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Kronborg]]></surname>
<given-names><![CDATA[MB]]></given-names>
</name>
<name>
<surname><![CDATA[Michowitz]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Auricchio]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Barbash]]></surname>
<given-names><![CDATA[IM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy]]></article-title>
<source><![CDATA[Europace]]></source>
<year>2022</year>
<volume>24</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>71-164</page-range></nlm-citation>
</ref>
<ref id="B114">
<label>114</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cheung]]></surname>
<given-names><![CDATA[CC]]></given-names>
</name>
<name>
<surname><![CDATA[Roston]]></surname>
<given-names><![CDATA[TM]]></given-names>
</name>
<name>
<surname><![CDATA[Andrade]]></surname>
<given-names><![CDATA[JG]]></given-names>
</name>
<name>
<surname><![CDATA[Bennett]]></surname>
<given-names><![CDATA[MT]]></given-names>
</name>
<name>
<surname><![CDATA[Davis]]></surname>
<given-names><![CDATA[MK]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Arrhythmias in cardiac amyloidosis:challenges in risk stratification and treatment]]></article-title>
<source><![CDATA[Can J Cardiol]]></source>
<year>2020</year>
<volume>36</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>416-23</page-range></nlm-citation>
</ref>
<ref id="B115">
<label>115</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Maurer]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[Kale]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Fontana]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Berk]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Grogan]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Gustafsson]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Patisiran treatment in patients with transthyretin cardiac amyloidosis]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2023</year>
<volume>389</volume>
<numero>17</numero>
<issue>17</issue>
<page-range>1553-65</page-range></nlm-citation>
</ref>
<ref id="B116">
<label>116</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Siddiqi]]></surname>
<given-names><![CDATA[OK]]></given-names>
</name>
<name>
<surname><![CDATA[Mints]]></surname>
<given-names><![CDATA[YY]]></given-names>
</name>
<name>
<surname><![CDATA[Berk]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Connors]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Doros]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Gopal]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diflunisal treatment is associated with improved survival for patients with early stage wild-type transthyretin (ATTR) amyloid cardiomyopathy:the Boston University Amyloidosis Center experience]]></article-title>
<source><![CDATA[Amyloid]]></source>
<year>2022</year>
<volume>29</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>71-8</page-range></nlm-citation>
</ref>
<ref id="B117">
<label>117</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Maurer]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[Schwartz]]></surname>
<given-names><![CDATA[JH]]></given-names>
</name>
<name>
<surname><![CDATA[Gundapaneni]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Elliott]]></surname>
<given-names><![CDATA[PM]]></given-names>
</name>
<name>
<surname><![CDATA[Merlini]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Waddington-Cruz]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2018</year>
<volume>379</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1007-16</page-range></nlm-citation>
</ref>
<ref id="B118">
<label>118</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Damy]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Garcia-Pavia]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Hanna]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Judge]]></surname>
<given-names><![CDATA[DP]]></given-names>
</name>
<name>
<surname><![CDATA[Merlini]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Gundapaneni]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension study]]></article-title>
<source><![CDATA[Eur J Heart Fail]]></source>
<year>2021</year>
<volume>23</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>277-85</page-range></nlm-citation>
</ref>
<ref id="B119">
<label>119</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gillmore]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
<name>
<surname><![CDATA[Judge]]></surname>
<given-names><![CDATA[DP]]></given-names>
</name>
<name>
<surname><![CDATA[Cappelli]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Fontana]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Garcia-Pavia]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Gibbs]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2024</year>
<volume>390</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>132-42</page-range></nlm-citation>
</ref>
<ref id="B120">
<label>120</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Karlstedt]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Jimenez-Zepeda]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Howlett]]></surname>
<given-names><![CDATA[JG]]></given-names>
</name>
<name>
<surname><![CDATA[White]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Fine]]></surname>
<given-names><![CDATA[NM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical experience with the use of doxycycline and ursodeoxycholic acid for the treatment of transthyretin cardiac amyloidosis]]></article-title>
<source><![CDATA[J Card Fail]]></source>
<year>2019</year>
<volume>25</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>147-53</page-range></nlm-citation>
</ref>
<ref id="B121">
<label>121</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[aus dem Siepen]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Bauer]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Aurich]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Buss]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
<name>
<surname><![CDATA[Steen]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Altland]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Green tea extract as a treatment for patients with wild-type transthyretin amyloidosis:an observational study]]></article-title>
<source><![CDATA[Drug Des Devel Ther]]></source>
<year>2015</year>
<volume>9</volume>
<page-range>6319-25</page-range></nlm-citation>
</ref>
<ref id="B122">
<label>122</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Macedo]]></surname>
<given-names><![CDATA[AVS]]></given-names>
</name>
<name>
<surname><![CDATA[Schwartzmann]]></surname>
<given-names><![CDATA[PV]]></given-names>
</name>
<name>
<surname><![CDATA[de Gusmão]]></surname>
<given-names><![CDATA[BM]]></given-names>
</name>
<name>
<surname><![CDATA[de Melo]]></surname>
<given-names><![CDATA[MDT]]></given-names>
</name>
<name>
<surname><![CDATA[Coelho-Filho]]></surname>
<given-names><![CDATA[OR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Advances in the treatment of cardiac amyloidosis]]></article-title>
<source><![CDATA[Curr Treat Options Oncol]]></source>
<year>2020</year>
<volume>21</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>36</page-range></nlm-citation>
</ref>
<ref id="B123">
<label>123</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Milani]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Merlini]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Palladini]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Light chain amyloidosis]]></article-title>
<source><![CDATA[Mediterr J Hematol Infect Dis]]></source>
<year>2018</year>
<volume>10</volume>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
<ref id="B124">
<label>124</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Palladini]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Schönland]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Merlini]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Milani]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Jaccard]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Bridoux]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The management of light chain (AL) amyloidosis in Europe:clinical characteristics, treatment patterns, and efficacy outcomes between 2004 and 2018]]></article-title>
<source><![CDATA[Blood Cancer J]]></source>
<year>2023</year>
<volume>13</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>19</page-range></nlm-citation>
</ref>
<ref id="B125">
<label>125</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Leung]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Bridoux]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Nasr]]></surname>
<given-names><![CDATA[SH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Monoclonal gammopathy of renal significance]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2021</year>
<volume>384</volume>
<numero>20</numero>
<issue>20</issue>
<page-range>1931-41</page-range></nlm-citation>
</ref>
<ref id="B126">
<label>126</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Oe]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Soma]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Sato]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Ito]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Heavy chain deposition disease:An overview]]></article-title>
<source><![CDATA[Clin Exp Nephrol]]></source>
<year>2013</year>
<volume>17</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>771-8</page-range></nlm-citation>
</ref>
<ref id="B127">
<label>127</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ihne]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Morbach]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Obici]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Palladini]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Störk]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Amyloidosis in heart failure]]></article-title>
<source><![CDATA[Curr Heart Fail Rep]]></source>
<year>2019</year>
<volume>16</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>285-303</page-range></nlm-citation>
</ref>
<ref id="B128">
<label>128</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Palladini]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Russo]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Bosoni]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Verga]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Sarais]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Lavatelli]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Identification of amyloidogenic light chains requires the combination of serum-free light chain assay with immunofixation of serum and urine]]></article-title>
<source><![CDATA[Clin Chem]]></source>
<year>2009</year>
<volume>55</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>499-504</page-range></nlm-citation>
</ref>
<ref id="B129">
<label>129</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Madan]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Dispenzieri]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Lacy]]></surname>
<given-names><![CDATA[MQ]]></given-names>
</name>
<name>
<surname><![CDATA[Buadi]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Hayman]]></surname>
<given-names><![CDATA[SR]]></given-names>
</name>
<name>
<surname><![CDATA[Zeldenrust]]></surname>
<given-names><![CDATA[SR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical features and treatment response of light chain (AL) amyloidosis diagnosed in patients with previous diagnosis of multiple myeloma]]></article-title>
<source><![CDATA[Mayo Clin Proc]]></source>
<year>2010</year>
<volume>85</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>232-8</page-range></nlm-citation>
</ref>
<ref id="B130">
<label>130</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rajkumar]]></surname>
<given-names><![CDATA[SV]]></given-names>
</name>
<name>
<surname><![CDATA[Gertz]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Kyle]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Primary systemic amyloidosis with delayed progression to multiple myeloma]]></article-title>
<source><![CDATA[Cancer]]></source>
<year>1998</year>
<volume>82</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>1501-5</page-range></nlm-citation>
</ref>
<ref id="B131">
<label>131</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rajkumar]]></surname>
<given-names><![CDATA[SV]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Multiple myeloma:2016 update on diagnosis, risk-stratification, and management]]></article-title>
<source><![CDATA[Am J Hematol]]></source>
<year>2016</year>
<volume>91</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>719-34</page-range></nlm-citation>
</ref>
<ref id="B132">
<label>132</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Eder]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Bitterman]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Images in clinical medicine Amyloid Purpura]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2007</year>
<volume>356</volume>
<numero>23</numero>
<issue>23</issue>
<page-range>2406</page-range></nlm-citation>
</ref>
<ref id="B133">
<label>133</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mumford]]></surname>
<given-names><![CDATA[AD]]></given-names>
</name>
<name>
<surname><![CDATA[O'Donnell]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Gillmore]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
<name>
<surname><![CDATA[Manning]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Hawkins]]></surname>
<given-names><![CDATA[PN]]></given-names>
</name>
<name>
<surname><![CDATA[Laffan]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Bleeding symptoms and coagulation abnormalities in 337 patients with AL-amyloidosis]]></article-title>
<source><![CDATA[Br J Haematol]]></source>
<year>2000</year>
<volume>110</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>454-60</page-range></nlm-citation>
</ref>
<ref id="B134">
<label>134</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bochtler]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Hegenbart]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Kunz]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Granzow]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Benner]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Seckinger]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Translocation t(11;14) is associated with adverse outcome in patients with newly diagnosed AL amyloidosis when treated with bortezomib-based regimens]]></article-title>
<source><![CDATA[J Clin Oncol]]></source>
<year>2015</year>
<volume>33</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>1371-8</page-range></nlm-citation>
</ref>
<ref id="B135">
<label>135</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kastritis]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Palladini]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Minnema]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[Wechalekar]]></surname>
<given-names><![CDATA[AD]]></given-names>
</name>
<name>
<surname><![CDATA[Jaccard]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[HC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Daratumumab-based treatment for immunoglobulin light-chain amyloidosis]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2021</year>
<volume>385</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>46-58</page-range></nlm-citation>
</ref>
<ref id="B136">
<label>136</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Merlini]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Dispenzieri]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Sanchorawala]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Schönland]]></surname>
<given-names><![CDATA[SO]]></given-names>
</name>
<name>
<surname><![CDATA[Palladini]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Hawkins]]></surname>
<given-names><![CDATA[PN]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Systemic immunoglobulin light chain amyloidosis]]></article-title>
<source><![CDATA[Nat Rev Dis Primers]]></source>
<year>2018</year>
<volume>4</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>38</page-range></nlm-citation>
</ref>
<ref id="B137">
<label>137</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bhutani]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Lentzsch]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diagnosis and management of systemic light chain AL amyloidosis]]></article-title>
<source><![CDATA[Pharmacol Ther]]></source>
<year>2020</year>
<volume>214</volume>
<page-range>107612</page-range></nlm-citation>
</ref>
<ref id="B138">
<label>138</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Manwani]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Cohen]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Sharpley]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Mahmood]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Sachchithanantham]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Foard]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib]]></article-title>
<source><![CDATA[Blood]]></source>
<year>2019</year>
<volume>134</volume>
<numero>25</numero>
<issue>25</issue>
<page-range>2271-80</page-range></nlm-citation>
</ref>
<ref id="B139">
<label>139</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Decotto]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Villanueva]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[de Arenaza Pérez]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Nucifora]]></surname>
<given-names><![CDATA[EM]]></given-names>
</name>
<name>
<surname><![CDATA[Aguirre]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Posadas-Martínez]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Heart transplantation in amyloidosis]]></article-title>
<source><![CDATA[Clinical and imaging manifestations. Arch Cardiol Mex]]></source>
<year>2022</year>
<volume>92</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>320-6</page-range></nlm-citation>
</ref>
<ref id="B140">
<label>140</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mehra]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
<name>
<surname><![CDATA[Canter]]></surname>
<given-names><![CDATA[CE]]></given-names>
</name>
<name>
<surname><![CDATA[Hannan]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
<name>
<surname><![CDATA[Semigran]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Uber]]></surname>
<given-names><![CDATA[PA]]></given-names>
</name>
<name>
<surname><![CDATA[Baran]]></surname>
<given-names><![CDATA[DA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation:A 10-year update]]></article-title>
<source><![CDATA[J Heart Lung Transplant]]></source>
<year>2016</year>
<volume>35</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1-23</page-range></nlm-citation>
</ref>
<ref id="B141">
<label>141</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hsich]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Singh]]></surname>
<given-names><![CDATA[TP]]></given-names>
</name>
<name>
<surname><![CDATA[Cherikh]]></surname>
<given-names><![CDATA[WS]]></given-names>
</name>
<name>
<surname><![CDATA[Harhay]]></surname>
<given-names><![CDATA[MO]]></given-names>
</name>
<name>
<surname><![CDATA[Hayes]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Perch]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The International thoracic organ transplant registry of the international society for heart and lung transplantation:Thirty-ninth adult heart transplantation report&#8211;2022;focus on transplant for restrictive heart disease]]></article-title>
<source><![CDATA[J Heart Lung Transplant]]></source>
<year>2022</year>
<volume>41</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>1366-75</page-range></nlm-citation>
</ref>
<ref id="B142">
<label>142</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sousa]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Monohan]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Rajagopalan]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Grigorian]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Guglin]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Heart transplantation in cardiac amyloidosis]]></article-title>
<source><![CDATA[Vol. 22, Heart Failure Reviews. Springer New York LLC]]></source>
<year>2017</year>
<page-range>317-27</page-range></nlm-citation>
</ref>
<ref id="B143">
<label>143</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Davis]]></surname>
<given-names><![CDATA[MK]]></given-names>
</name>
<name>
<surname><![CDATA[Kale]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Liedtke]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Schrier]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Arai]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Wheeler]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Outcomes after heart transplantation for amyloid cardiomyopathy in the modern era]]></article-title>
<source><![CDATA[Am J Transplant]]></source>
<year>2015</year>
<volume>15</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>650-8</page-range></nlm-citation>
</ref>
<ref id="B144">
<label>144</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vilas-Boas]]></surname>
<given-names><![CDATA[M do C]]></given-names>
</name>
<name>
<surname><![CDATA[Rocha]]></surname>
<given-names><![CDATA[AP]]></given-names>
</name>
<name>
<surname><![CDATA[Cardoso]]></surname>
<given-names><![CDATA[MN]]></given-names>
</name>
<name>
<surname><![CDATA[Fernandes]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Coelho]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Cunha]]></surname>
<given-names><![CDATA[JPS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical 3-D gait assessment of patients with polyneuropathy associated with hereditary transthyretin amyloidosis]]></article-title>
<source><![CDATA[Front Neurol]]></source>
<year>2020</year>
<volume>11</volume>
<page-range>605282</page-range></nlm-citation>
</ref>
<ref id="B145">
<label>145</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dasgupta]]></surname>
<given-names><![CDATA[NR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Care of patients with transthyretin amyloidosis:the roles of nutrition, supplements, exercise, and mental health]]></article-title>
<source><![CDATA[Am J Cardiol]]></source>
<year>2022</year>
<volume>185</volume>
<page-range>S35-42</page-range></nlm-citation>
</ref>
<ref id="B146">
<label>146</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Argirò]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Silverii]]></surname>
<given-names><![CDATA[MV]]></given-names>
</name>
<name>
<surname><![CDATA[Burgisser]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Fattirolli]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Baldasseroni]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[di Mario]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Serial changes in cardiopulmonary exercise testing parameters in untreated patients with transthyretin cardiac amyloidosis]]></article-title>
<source><![CDATA[Can J Cardiol]]></source>
<year>2024</year>
<volume>40</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>364-9</page-range></nlm-citation>
</ref>
<ref id="B147">
<label>147</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Banydeen]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Monfort]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Inamo]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Neviere]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diagnostic and prognostic values of cardiopulmonary exercise testing in cardiac amyloidosis]]></article-title>
<source><![CDATA[Front Cardiovasc Med]]></source>
<year>2022</year>
<volume>9</volume>
<page-range>898033</page-range></nlm-citation>
</ref>
<ref id="B148">
<label>148</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bartolini]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Baldasseroni]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Fattirolli]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Silverii]]></surname>
<given-names><![CDATA[MV]]></given-names>
</name>
<name>
<surname><![CDATA[Piccioli]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Perfetto]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Poor right ventricular function is associated with impaired exercise capacity and ventilatory efficiency in transthyretin cardiac amyloid patients]]></article-title>
<source><![CDATA[Intern Emerg Med]]></source>
<year>2021</year>
<volume>16</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>653-60</page-range></nlm-citation>
</ref>
<ref id="B149">
<label>149</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yunis]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Doros]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Luptak]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Connors]]></surname>
<given-names><![CDATA[LH]]></given-names>
</name>
<name>
<surname><![CDATA[Sam]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Use of ventilatory efficiency slope as a marker for increased mortality in wild-type transthyretin cardiac amyloidosis]]></article-title>
<source><![CDATA[Am J Cardiol]]></source>
<year>2019</year>
<volume>124</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>122-30</page-range></nlm-citation>
</ref>
<ref id="B150">
<label>150</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cantone]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Serenelli]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Sanguettoli]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Maio]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Fabbri]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Dal Passo]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cardiopulmonary exercise testing predicts prognosis in amyloid cardiomyopathy:a systematic review and meta-analysis]]></article-title>
<source><![CDATA[ESC Heart Fail]]></source>
<year>2023</year>
<volume>10</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>2740-4</page-range></nlm-citation>
</ref>
<ref id="B151">
<label>151</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Silverii]]></surname>
<given-names><![CDATA[MV]]></given-names>
</name>
<name>
<surname><![CDATA[Argirò]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Baldasseroni]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Fumagalli]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Zampieri]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Guerrieri]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prognostic value of cardiopulmonary exercise testing in patients with transthyretin cardiac amyloidosis]]></article-title>
<source><![CDATA[Intern Emerg Med]]></source>
<year>2023</year>
<volume>18</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>585-93</page-range></nlm-citation>
</ref>
<ref id="B152">
<label>152</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Banydeen]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Eggleston]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Deney]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Monfort]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Ryu]]></surname>
<given-names><![CDATA[JH]]></given-names>
</name>
<name>
<surname><![CDATA[Vergaro]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Risk stratification in transthyretin cardiac amyloidosis:the added value of lung spirometry]]></article-title>
<source><![CDATA[J Clin Med]]></source>
<year>2023</year>
<volume>12</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>3684</page-range></nlm-citation>
</ref>
<ref id="B153">
<label>153</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dalia]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Acharya]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Chan]]></surname>
<given-names><![CDATA[WC]]></given-names>
</name>
<name>
<surname><![CDATA[Sauer]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Weidling]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Fritzlen]]></surname>
<given-names><![CDATA[JG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prognostic role of cardiopulmonary exercise testing in wild-type transthyretin amyloid cardiomyopathy patients treated with tafamidis]]></article-title>
<source><![CDATA[J Card Fail]]></source>
<year>2021</year>
<volume>27</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1285-9</page-range></nlm-citation>
</ref>
<ref id="B154">
<label>154</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Swank]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Horton]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Fleg]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Fonarow]]></surname>
<given-names><![CDATA[GC]]></given-names>
</name>
<name>
<surname><![CDATA[Keteyian]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Goldberg]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Modest increase in peak VO2 is related to better clinical outcomes in chronic heart failure patients:Results from Heart Failure and a Controlled Trial to Investigate Outcomes of Exercise Training]]></article-title>
<source><![CDATA[Circ Heart Fail]]></source>
<year>2012</year>
<volume>5</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>579-85</page-range></nlm-citation>
</ref>
<ref id="B155">
<label>155</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dhakal]]></surname>
<given-names><![CDATA[BP]]></given-names>
</name>
<name>
<surname><![CDATA[Malhotra]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Murphy]]></surname>
<given-names><![CDATA[RM]]></given-names>
</name>
<name>
<surname><![CDATA[Pappagianopoulos]]></surname>
<given-names><![CDATA[PP]]></given-names>
</name>
<name>
<surname><![CDATA[Baggish]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
<name>
<surname><![CDATA[Weiner]]></surname>
<given-names><![CDATA[RB]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mechanisms of exercise intolerance in heart failure with preserved ejection fraction:The role of abnormal peripheral oxygen extraction]]></article-title>
<source><![CDATA[Circ Heart Fail]]></source>
<year>2015</year>
<volume>8</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>286-94</page-range></nlm-citation>
</ref>
<ref id="B156">
<label>156</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Clemmensen]]></surname>
<given-names><![CDATA[TS]]></given-names>
</name>
<name>
<surname><![CDATA[Soerensen]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Hansson]]></surname>
<given-names><![CDATA[NH]]></given-names>
</name>
<name>
<surname><![CDATA[Tolbod]]></surname>
<given-names><![CDATA[LP]]></given-names>
</name>
<name>
<surname><![CDATA[Harms]]></surname>
<given-names><![CDATA[HJ]]></given-names>
</name>
<name>
<surname><![CDATA[Eiskjær]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Myocardial oxygen consumption and efficiency in patients with cardiac amyloidosis]]></article-title>
<source><![CDATA[J Am Heart Assoc]]></source>
<year>201</year>
<volume>7</volume>
<numero>21</numero>
<issue>21</issue>
</nlm-citation>
</ref>
<ref id="B157">
<label>157</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rapezzi]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Milandri]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Lorenzini]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The complex interplay between systolic and diastolic function at rest and during exercise in heart failure:the case of cardiac amyloidosis]]></article-title>
<source><![CDATA[Eur J Heart Fail]]></source>
<year>2017</year>
<volume>19</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1466-7</page-range></nlm-citation>
</ref>
<ref id="B158">
<label>158</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Xin]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Hu]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Hu]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Sun]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Zhao]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prognostic impact of light-chain and transthyretin-related categories in cardiac amyloidosis:A systematic review and meta-analysis]]></article-title>
<source><![CDATA[Hellenic J Cardiol]]></source>
<year>2019</year>
<volume>60</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>375-83</page-range></nlm-citation>
</ref>
<ref id="B159">
<label>159</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nakahashi]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Arita]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Yamaji]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Inoue]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Yokota]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Hoshii]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Impact of clinical and echocardiographic characteristics on occurrence of cardiac events in cardiac amyloidosis as proven by endomyocardial biopsy]]></article-title>
<source><![CDATA[Int J Cardiol]]></source>
<year>2014</year>
<volume>176</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>753-9</page-range></nlm-citation>
</ref>
<ref id="B160">
<label>160</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lane]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Fontana]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Martinez-Naharro]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Quarta]]></surname>
<given-names><![CDATA[CC]]></given-names>
</name>
<name>
<surname><![CDATA[Whelan]]></surname>
<given-names><![CDATA[CJ]]></given-names>
</name>
<name>
<surname><![CDATA[Petrie]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Natural history, quality of life, and outcome in cardiac transthyretin amyloidosis]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2019</year>
<volume>140</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>16-26</page-range></nlm-citation>
</ref>
<ref id="B161">
<label>161</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bhuiyan]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Helmke]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Patel]]></surname>
<given-names><![CDATA[AR]]></given-names>
</name>
<name>
<surname><![CDATA[Ruberg]]></surname>
<given-names><![CDATA[FL]]></given-names>
</name>
<name>
<surname><![CDATA[Packman]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Cheung]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pressure-volume relationships in patients with transthyretin (ATTR) cardiac amyloidosis secondary to V122i mutations and wild-type transthyretin transthyretin cardiac amyloid study (TRACS)]]></article-title>
<source><![CDATA[Circ Heart Fail]]></source>
<year>2011</year>
<volume>4</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>121-8</page-range></nlm-citation>
</ref>
<ref id="B162">
<label>162</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ruberg]]></surname>
<given-names><![CDATA[FL]]></given-names>
</name>
<name>
<surname><![CDATA[Maurer]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[Judge]]></surname>
<given-names><![CDATA[DP]]></given-names>
</name>
<name>
<surname><![CDATA[Zeldenrust]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Skinner]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[AY]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy:The Transthyretin Amyloidosis Cardiac Study (TRACS)]]></article-title>
<source><![CDATA[Am Heart J]]></source>
<year>2012</year>
<volume>164</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>222-228.e1</page-range></nlm-citation>
</ref>
<ref id="B163">
<label>163</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Miller]]></surname>
<given-names><![CDATA[AB]]></given-names>
</name>
<name>
<surname><![CDATA[Januzzi]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[O'Neill]]></surname>
<given-names><![CDATA[BJ]]></given-names>
</name>
<name>
<surname><![CDATA[Gundapaneni]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Patterson]]></surname>
<given-names><![CDATA[TA]]></given-names>
</name>
<name>
<surname><![CDATA[Sultan]]></surname>
<given-names><![CDATA[MB]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Causes of cardiovascular hospitalization and death in patients with transthyretin amyloid cardiomyopathy (from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial [ATTR-ACT])]]></article-title>
<source><![CDATA[Am J Cardiol]]></source>
<year>2021</year>
<volume>148</volume>
<page-range>146-50</page-range></nlm-citation>
</ref>
<ref id="B164">
<label>164</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rubin]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Steidley]]></surname>
<given-names><![CDATA[DE]]></given-names>
</name>
<name>
<surname><![CDATA[Carlsson]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Mohlim]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Maurer]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Myocardial contraction fraction by M-mode echocardiography is superior to ejection fraction in predicting mortality in transthyretin amyloidosis]]></article-title>
<source><![CDATA[J Card Fail]]></source>
<year>2018</year>
<volume>24</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>504-11</page-range></nlm-citation>
</ref>
<ref id="B165">
<label>165</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Milani]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Dispenzieri]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Scott]]></surname>
<given-names><![CDATA[CG]]></given-names>
</name>
<name>
<surname><![CDATA[Gertz]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Perlini]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Mussinelli]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Independent prognostic value of stroke volume index in patients with immunoglobulin light chain amyloidosis]]></article-title>
<source><![CDATA[Circ Cardiovasc Imaging]]></source>
<year>2018</year>
<volume>11</volume>
<numero>5</numero>
<issue>5</issue>
</nlm-citation>
</ref>
<ref id="B166">
<label>166</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Feng]]></surname>
<given-names><![CDATA[KY]]></given-names>
</name>
<name>
<surname><![CDATA[Loungani]]></surname>
<given-names><![CDATA[RS]]></given-names>
</name>
<name>
<surname><![CDATA[Rao]]></surname>
<given-names><![CDATA[VN]]></given-names>
</name>
<name>
<surname><![CDATA[Patel]]></surname>
<given-names><![CDATA[CB]]></given-names>
</name>
<name>
<surname><![CDATA[Khouri]]></surname>
<given-names><![CDATA[MG]]></given-names>
</name>
<name>
<surname><![CDATA[Felker]]></surname>
<given-names><![CDATA[GM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Best practices for prognostic evaluation of a patient with transthyretin amyloid cardiomyopathy]]></article-title>
<source><![CDATA[JACC CardioOncol]]></source>
<year>2019</year>
<volume>1</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>273-9</page-range></nlm-citation>
</ref>
<ref id="B167">
<label>167</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Grogan]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Scott]]></surname>
<given-names><![CDATA[CG]]></given-names>
</name>
<name>
<surname><![CDATA[Kyle]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Zeldenrust]]></surname>
<given-names><![CDATA[SR]]></given-names>
</name>
<name>
<surname><![CDATA[Gertz]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Lin]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>2016</year>
<volume>68</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>1014-20</page-range></nlm-citation>
</ref>
<ref id="B168">
<label>168</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gillmore]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
<name>
<surname><![CDATA[Damy]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Fontana]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Hutchinson]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Lachmann]]></surname>
<given-names><![CDATA[HJ]]></given-names>
</name>
<name>
<surname><![CDATA[Martinez-Naharro]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A new staging system for cardiac transthyretin amyloidosis]]></article-title>
<source><![CDATA[Eur Heart J]]></source>
<year>2018</year>
<volume>39</volume>
<numero>30</numero>
<issue>30</issue>
<page-range>2799-806</page-range></nlm-citation>
</ref>
<ref id="B169">
<label>169</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kumar]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Dispenzieri]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Lacy]]></surname>
<given-names><![CDATA[MQ]]></given-names>
</name>
<name>
<surname><![CDATA[Hayman]]></surname>
<given-names><![CDATA[SR]]></given-names>
</name>
<name>
<surname><![CDATA[Buadi]]></surname>
<given-names><![CDATA[FK]]></given-names>
</name>
<name>
<surname><![CDATA[Colby]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements]]></article-title>
<source><![CDATA[J Clin Oncol]]></source>
<year>2012</year>
<volume>30</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>989-95</page-range></nlm-citation>
</ref>
<ref id="B170">
<label>170</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gillmore]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
<name>
<surname><![CDATA[Reilly]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
<name>
<surname><![CDATA[Coats]]></surname>
<given-names><![CDATA[CJ]]></given-names>
</name>
<name>
<surname><![CDATA[Cooper]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Cox]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Coyne]]></surname>
<given-names><![CDATA[MRE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical and genetic evaluation of people with or at risk of hereditary ATTR amyloidosis:an expert opinion and consensus on Best Practice in Ireland and the UK]]></article-title>
<source><![CDATA[Adv Ther]]></source>
<year>2022</year>
<volume>39</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>2292-301</page-range></nlm-citation>
</ref>
<ref id="B171">
<label>171</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Grandis]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Obici]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Luigetti]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Briani]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Benedicenti]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Bisogni]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Recommendations for pre-symptomatic genetic testing for hereditary transthyretin amyloidosis in the era of effective therapy:a multicenter Italian consensus]]></article-title>
<source><![CDATA[Orphanet J Rare Dis]]></source>
<year>2020</year>
<volume>15</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>348</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
